Helsinn is a privately-owned Swiss Pharma Group with an extensive portfolio of marketed innovative cancer and rare disease therapies and a robust drug development pipeline. Since 1976, Helsinn has been improving the lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model. Headquartered in Switzerland, with operating subsidiaries in the U.S., China, Monaco and manufacturing sites in Switzerland and Ireland.
Brands: https://helsinnvirtualconference.com/asco2021/Banner1140x250px.jpg
Press Releases